Industry
Biotechnology
Citius Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and commercialization of critical care products focusing on anti-infective products in adjunct cancer care, prescription products, and mesenchymal stem cell therapy. The company is developing five proprietary products comprising Mino-Lok, an antibiotic lock solution to treat patients with catheter-related bloodstream infections by salvaging the infected catheter; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; Halo-Lido, a corticosteroid-lidocaine topical formulation that intends to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids; NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory disease syndrome; and I/ONTAK, an engineered IL-2 diphtheria toxin fusion protein for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma. Citius Pharmaceuticals, Inc. was founded in 2007 and is headquartered in Cranford, New Jersey.
Loading...
Open
0.36
Mkt cap
69M
Volume
2.9M
High
0.42
P/E Ratio
-1.59
52-wk high
1.07
Low
0.36
Div yield
N/A
52-wk low
0.31
Portfolio Pulse from Benzinga Newsdesk
September 05, 2024 | 12:34 pm
Portfolio Pulse from Benzinga Newsdesk
August 19, 2024 | 11:09 am
Portfolio Pulse from Benzinga Newsdesk
August 13, 2024 | 1:57 pm
Portfolio Pulse from Benzinga Newsdesk
August 12, 2024 | 9:41 pm
Portfolio Pulse from Vandana Singh
August 08, 2024 | 9:41 pm
Portfolio Pulse from Benzinga Newsdesk
August 08, 2024 | 4:59 pm
Portfolio Pulse from Benzinga Newsdesk
August 08, 2024 | 11:50 am
Portfolio Pulse from Benzinga Newsdesk
August 05, 2024 | 12:06 pm
Portfolio Pulse from Benzinga Newsdesk
July 15, 2024 | 1:44 pm
Portfolio Pulse from Benzinga Newsdesk
May 31, 2024 | 5:06 pm
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.